Platelets Journal Welcomes Sarah Westbury as Principal Editor to the Editorial Board
Platelets Journal shared a post on LinkedIn:
“We are delighted to welcome Sarah Westbury as a newly appointed Principal Editor to the Platelet editorial board!
Westbury is a Consultant Senior Lecturer in Haematology at the University of Bristol and a Consultant Haematologist at University Hospitals Bristol and Weston NHS Foundation Trust.
Westbury has extensive experience as a clinician and researcher investigating inherited haematological disorders, with a particular interest in rare diseases that perturb platelet number and function.
Explore some of Westbury’s recent collaborations published in Platelets below.”
Title: ACTN1 variants associated with thrombocytopenia
Authors: Sarah K. Westbury, Deborah K. Shoemark, Andrew D. Mumford
Read the Full Article on Platelets.

Title: TUBB1 variants and human platelet traits
Authors: Kate Burley, Sarah K Westbury, Andrew D Mumford
Read the Full Article on Platelets.

Title: FLNA variants associated with disorders of platelet number or function
Authors: Pietro Vassallo, Sarah K Westbury, Andrew D Mumford
Read the Full Article on Platelets.

Stay updated with Hemostasis Today.
-
Apr 15, 2026, 04:52Ulrich Pecks: Personalized Approaches to VTE Prevention in Pregnant Women with Inherited Thrombophilia
-
Apr 15, 2026, 04:06Brenda Pleasant: Insights from the HFA Symposium on Hemophilia Care
-
Apr 15, 2026, 03:43Lexy Halloran: Addressing Diagnostic Inequities in Women with Chronic Conditions
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids